Cantor Fitzgerald Weighs in on Ascendis Pharma A/S’s FY2022 Earnings (NASDAQ:ASND)

Ascendis Pharma A/S (NASDAQ:ASNDGet Rating) – Cantor Fitzgerald issued their FY2022 earnings estimates for shares of Ascendis Pharma A/S in a report issued on Wednesday, September 21st. Cantor Fitzgerald analyst L. Watsek forecasts that the biotechnology company will earn ($9.07) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Ascendis Pharma A/S’s current full-year earnings is ($8.69) per share. Cantor Fitzgerald also issued estimates for Ascendis Pharma A/S’s FY2023 earnings at ($10.94) EPS.

A number of other brokerages also recently commented on ASND. Oppenheimer dropped their price objective on shares of Ascendis Pharma A/S from $154.00 to $144.00 and set an “outperform” rating on the stock in a research report on Thursday, August 11th. Wells Fargo & Company increased their target price on shares of Ascendis Pharma A/S from $167.00 to $172.00 and gave the company an “overweight” rating in a research report on Thursday. Morgan Stanley dropped their target price on shares of Ascendis Pharma A/S from $152.00 to $148.00 and set an “overweight” rating on the stock in a research report on Thursday, August 11th. Berenberg Bank reaffirmed a “buy” rating and issued a $166.00 target price on shares of Ascendis Pharma A/S in a research report on Tuesday, August 30th. Finally, SVB Leerink dropped their target price on shares of Ascendis Pharma A/S from $174.00 to $168.00 and set an “outperform” rating on the stock in a research report on Thursday, August 11th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $153.70.

Ascendis Pharma A/S Trading Down 2.0 %

Shares of NASDAQ:ASND opened at $103.88 on Friday. Ascendis Pharma A/S has a 52 week low of $61.58 and a 52 week high of $172.65. The company’s 50 day moving average is $94.55 and its two-hundred day moving average is $96.67. The company has a current ratio of 9.66, a quick ratio of 8.78 and a debt-to-equity ratio of 0.82. The company has a market cap of $5.92 billion, a PE ratio of -13.17 and a beta of 0.66.

Ascendis Pharma A/S (NASDAQ:ASNDGet Rating) last announced its quarterly earnings data on Wednesday, August 10th. The biotechnology company reported ($1.54) EPS for the quarter, beating analysts’ consensus estimates of ($2.11) by $0.57. Ascendis Pharma A/S had a negative net margin of 2,099.51% and a negative return on equity of 48.92%. The company had revenue of $6.51 million for the quarter, compared to the consensus estimate of $7.07 million.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD lifted its stake in shares of Ascendis Pharma A/S by 6.1% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 5,165,375 shares of the biotechnology company’s stock worth $480,173,000 after acquiring an additional 295,224 shares during the period. Wellington Management Group LLP lifted its stake in shares of Ascendis Pharma A/S by 14.6% in the 1st quarter. Wellington Management Group LLP now owns 4,665,579 shares of the biotechnology company’s stock worth $547,552,000 after acquiring an additional 594,855 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Ascendis Pharma A/S by 89.0% in the 2nd quarter. Goldman Sachs Group Inc. now owns 3,316,215 shares of the biotechnology company’s stock worth $308,275,000 after acquiring an additional 1,561,757 shares during the period. Invesco Ltd. lifted its stake in shares of Ascendis Pharma A/S by 1.4% in the 1st quarter. Invesco Ltd. now owns 1,017,090 shares of the biotechnology company’s stock worth $119,365,000 after acquiring an additional 14,047 shares during the period. Finally, Franklin Resources Inc. lifted its stake in shares of Ascendis Pharma A/S by 3.9% in the 2nd quarter. Franklin Resources Inc. now owns 958,037 shares of the biotechnology company’s stock worth $89,059,000 after acquiring an additional 36,356 shares during the period.

About Ascendis Pharma A/S

(Get Rating)

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia.

Read More

Earnings History and Estimates for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.